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INTRODUCTION
 Papillary carcinoma of the thyroid is the most common malignant tumor of the thyroid, 
accounting for 80% of all thyroid cancers. It occurs mostly commonly in women between 3rd to 
5th decades.
The  interplay  between  inflammatory  and  neoplastic  disorders,  firmly  established  in 
certain tissues,  is  a  matter  of  controversy in  the thyroid.  An increased risk for  developing 
papillary  carcinoma  in  patients  with  Hashimoto’s  thyroiditis  remains  controversial  ranging 
from 0-30%1
A marker found frequently in both of these thyroid disorders is described. Expression of 
p53 homologous nuclear protein p63 was surveyed in a spectrum of thyroid neoplasms and 
inflammatory disorders.  p63 is  postulated to regulate the stem cell  phenotype in squamous 
epithelia, and in tumors of squamous origin2.
This work aims at histologically classifying all the thyroid lesions and identifying the 
lesions of Hashimoto’s thyroiditis with papillary carcinoma, and establishing the pathobiologic 
link between the two by immunohistochemical detection of p63 in papillary thyroid carcinoma 
and Hashimoto’s thyroiditis. 
The expression of p63 protein in Hashimoto’s thyroiditis and papillary carcinoma has 
been  studied  in  this  work  to  address  the  postulate  of  a  common  origin  from a  stem cell 
precursor.
The  study  herein  describes  the  immunohistochemical  detection  of  p63  in  papillary 
carcinomas  of  thyroid,  Hashimoto’s  thyroiditis  and  Hashimoto’s  thyroiditis  with  papillary 
carcinoma  to  find  out  whether  p63  expression  may  constitute  a  mechanistic  link  between 
Hashimoto’s thyroiditis and papillary carcinoma.
AIMS AND OBJECTIVES
 To identify various thyroid lesions and classify them according to their 
morphology.
 To study the occurrence of papillary carcinoma in cases of thyroiditis and 
other thyroid lesions.
 To establish the association between Hashimoto’s thyroiditis and papillary 
carcinoma thyroid by immunohistochemical detection of p63 protein.
REVIEW OF LITERATURE
Thyroid  cancer  accounts  for  approximately  1%  of  all  malignancies  in  developed 
countries with an estimated annual incidence of 122,000 cases worldwide3.
Among epithelial tumors, carcinomas of follicular cell origin outnumber those of “C” 
Cell  origin.  Carcinomas  of  follicular  cell  origin  are  indolent  malignancies  with  10  year 
survivals in excess of 90% 4,5.
THE COMMONEST TUMORS AND THEIR FREQUENCIES.
Tumour type Frequency (%)
Papillary carcinoma 70-85%
Follicular carcinoma 5-10%
Medullary carcinoma 5%
Malignant lymphoma 4-5%
Undifferntiated carcinoma 2-5%
 Poorly differentiated 
(Insular carcinoma)
0.4-10%
According to surveillance Epidemiology and End results (SEER) study 10 year relative 
survival rates of major thyroid carcinomas are6 
Papillary carcinoma : 0.98
Follicular carcinoma :  0.92
Medullary carcinoma :  0.80
Undifferentiated carcinoma :  0.13
GENERALIZATION ON PRIMARY THYROID CANCERS
 Papillary carcinoma is the commonest histologic type
 With  the  exception  of  angiosarcoma,  tumors  are  2-4  times  more  frequent  in 
women  than  in  men7.  Female  sex  is  usually  associated  with  slightly  better 
prognosis.
 Better differentiated tumors generally occur in younger patients, while the less 
differentiated tumors occur in older patients
 The mean ages for low, intermediate and high grade tumors are the forties, fifties 
and sixties respectively.  
STAGING OF THYROID TUMORS (International  union  against  cancer)  Tumor, 
Node, Metastasis staging  
Tx : Primary tumor cannot be assessed
T0 : No evidence of primary tumor
T1 :  Tumor < 2cm, limited to thyroid
T2 :  Tumor >2cm but <4 cm, limited to the thyroid
T3 :  Tumor >4cm, limited to thyroid or tumor any size with 
minimal intrathyroid or perithyriod soft tissue extension
T4a : Tumor of any size invading beyond the thyroid capsule 
to  invade  subcutaneous  tissues,  larynx,  trachea,  esophagus  or  recurrent 
laryngeal nerve.
T4b :  Tumor invades prevertebral fascia or mediastinal vessels  
or encases carotid artery.
Nx : Regional lymphnodes cannot be assessed
N0 : No regional lymphnode metastasis
N1 : Regional lymphnode metastasis
N1a : Metastasis to pretracheal, paratracheal, and prelaryngeal/  
Delphian nodes.
N1b :  Metastasis to unilateral, bilateral, or contralateral cervical 
or upper / superior mediastinal nodes. 
DISTANT METASTASIS(M) 
Mx :  Distant metastasis cannot be assessed
Mo :  No distant metastasis
M1 :  Distant metastasis
Staging of thyroid tumors (International union against cancer)
< 45 years old > 45 years old
I Any T, Any N, Mo T1, No, Mo
II Any T, Any N, M1 T2, No, Mo
III
–
T3, No, Mo
T1/T2/T3, N1a, Mo
IVA
–
T4a, Any N, Mo
T1/T2/T3, N1b, Mo
IV B – T4b, Any N, Mo
IV C – Any T, Any N, M1
Papillary  carcinoma is  defined as a  malignant  epithelial  tumor  showing evidence of 
follicular cell differentiation and characterized by distinctive nuclear features. This is the most 
common malignant tumor of the gland in countries having iodine sufficient or iodine excess 
diets8 and comprises about 80% of thyroid malignancies. These common tumors tend to be 
biologically indolent and have excellent prognosis (more than 90% at 20 years)9,10. The tumors 
invade lymphatics leading to multifocal lesions and to regional lymph node metastasis. Venous 
invasion rarely occurs and metastases outside the neck is unusual (5-7% of cases)11,12. 
RISK  ASSIGNMENT  SYSTEMS  ARE  NOW  WIDELY  USED  TO  GUIDE 
TREATMENT13,14
Parameters assessed in AMES (Age, Metastasis, Extent of primary cancer and Tumor 
size) risk group definition systems.
Parameter Low Risk High Risk
Age Male <40 Yrs
Female <50 yrs
Male >40 years
Female >50 years
Metastasis No distant
Metastasis
Distant metastasis
Extent of 
primary 
cancer
Intra thyroidal 
papillary carcinoma
Extra thyroidal papillary 
carcinoma
Size < 5 cm > 5cm
OTHER RISK DEFINITION - SYSTEM OR PROGNOSTIC SCORES 
DAEMS 
Incorporating in addition tumor DNA Content as measured by flow cytometry 
AGES
Incorporating in addition tumor grade 
MACIS 
Incorporating in addition completeness of excision. 
Papillary carcinoma can occur at any age and rarely has been diagnosed as a congenital 
tumor15. Most tumors are diagnosed in patients between 3rd and 5th decades16,  17. Women are 
affected more than men in ratios of 2:1 to 4:118.
Etiological factors
The addition of iodine to the diet in endemic goiter areas in Europe has been associated 
with  a  decreased  incidence  of  follicular  cancer  and an  increase  in  papillary  carcinoma19,20. 
External radiation probably plays a role in the development of papillary cancer21,22. A great 
increase in the incidence of papillary carcinoma in Berlarus and the Ukraine has been apparent 
since the Chernobyl nuclear accident23. Some authors believe that patients with Graves disease 
have  a  higher  than  expected  incidence  of  papillary  cancer  24.  Other  studies  disagree25. 
Hashimoto’s thyroiditis, Familial adenomatous polyposis (FAP) or Cowden disease all increase 
the risk for papillary carcinoma26, 27.
Cytogenetics
Chromosomal  rearrangements  of  receptor  tyrosine  kinase  genes  (RET  and  TRK) 
represent  the  most  common  structural  genetic  alterations  in  papillary  thyroid  carcinoma. 
Rearrangements  involving  the  RET  gene  called  RET/PTC  are  found  with  highly  variable 
frequency in 0-80% of cases.
Average incidence of RET/PTC is 20-30% in sporadic adult papillary carcinomas28,  29 
and is higher in tumors from children and young adults 45-60%30 and in populations subjected 
to either accidental  or therapeutic irradiation (50-80%)31,32.  RET/PTC, is  typically the most 
common, followed by RET/PTC 333,34 whereas RET/PTC 2 and novel types35,36 account for 
<5% of all rearrangements.
TRK REARRANGEMENTS 
Chromosomal rearrangements involving in TRK gene are found in approximately 10% 
of papillary carcinomas. 
RAS MUTATIONS 
Activating point mutation of one of the three RAS proto oncogenes occur in less than 
10% of papillary carcinomas37,38. 
BRAF MUTATIONS 
Point mutations of the BRAF gene at nucleotide position 1796, a thymine to adenine 
transversion, has been identified in a high proportion of papillary carcinomas (up to 70%)39,40. 
Papillary carcinomas have been described in patients with Familial Adenomatous Polyposis 
Coli,  Cowden  syndrome,  Hereditary  Nonpolyposis  Colon  Cancer  syndrome,  Peutz  Jeghers 
syndrome and Ataxia telangiectasia41.
Macroscopy
Papillary carcinomas are typically infiltrative, with irregular ill defined borders and hard 
consistency, white to tan in colour, and a granular texture due to the presence of papillae .Cut 
surface  is  gritty  because  of  presence  of  psammoma  bodies  and  calcifications.  Multifocal 
disease is common in 65%42, 43.
Histological appearances
 The nuclei  of  papillary carcinoma are typically  large,  rounded,  avoid,  ground glass 
orphan  Annie  eye  nuclei  and  grooved  with  small  distinct  nucleoli.  This  feature  is  not 
pathognomonic,  because  benign  lesions  such  as  nodular  hyperplasia,  follicular  adenoma, 
Graves disease and Hashimoto’s thyroiditis can exhibit clear nuclei focally44, 45.
Nuclear grooving is not pathognomonic because it can be observed in solid cell nests, 
follicular  neoplasms,  hyalinizing  trabacular  adenomas,  poorly  differentiated  thyroid 
carcinomas, and adenocarcinomas of non-thyroid origin46. 
Nuclear pseudoinclusions, which represent intranuclear herniation pockets of cytoplasm, 
are typical but not pathognomonic, are found only in a minority of tumor cells47.
The neoplastic  cells  are polygonal to cuboidal,  but  can be attenuated,  dome shaped, 
hobnailed or columnar. Cytoplasm is lightly eosinophilic to amphophilic but can be oxyphilic 
or clear48,49. Stroma may show calcification or ossification50. 
The  papillae  encountered  in  nodular  goiter  and  follicular  adenoma  with  papillary 
hyperplasia are usually broad and have follicles in the cores. The lining cells are columnar with 
regular, non crowded, basally situated, dark, round nuclei resembling beads on string which is 
in striking contrast to the crowded and haphazardly oriented pale nuclei of papillary carcinoma. 
The papillae that occur in thyrotoxicosis, Hashimoto’s thyroiditis and toxic follicular 
adenoma are non branching short, stubby projections that protrude into the follicular lumen and 
lack  well  defined  fibrovascular  cores.  In  Hashimoto’s  thyroiditis  well  developed  nuclear 
features of papillary carcinoma are lacking although nuclear clearing is common. Papillae can 
occur in columnar carcinoma and medullary carcinoma but the nuclear features of papillary 
carcinoma  are  lacking.  Hurthle  cell  adenoma  /carcinoma  not  uncommonly  has  a  minor 
papillary component . The papillae are usually non arborizing and the cells do not show nuclear 
crowding. However occasional nuclear grooves can be present. Calcified colloid should not be 
mistaken for psammoma bodies.
Variants of papillary carcinoma
FOLLICULAR VARIANT OF PAPILLARY CARCINOMA
Papillary carcinoma composed entirely or almost exclusively of follicles is known as 
follicular variant of papillary carcinoma. Most cases grow in an infiltrative pattern. But some 
are encapsulated (so called Lindsay tumor).  Follicles  vary in size and shape,  but are often 
elongated or irregular shaped with abortive papillary formation, colloid is usually deep staining 
and  scalloped.  Psammoma  bodies  and  sclerosis  may  be  present.  Clinical  behavior  is  not 
different from conventional papillary carcinoma.
SOLID VARIANT 
Papillary carcinoma with more than 50% solid growth51,52 with no tumor necrosis53,54 is 
known as solid variant of papillary carcinoma. It is associated with a slightly higher frequency 
of  distant  metastasis  and  less  favourable  prognosis  compared  with  conventional  papillary 
carcinoma. 
ENCAPSULATED VARIANT
Encapsulated variant constitutes 4-14% of all papillary carcinomas. It’s fibrous capsule 
may or may not show invasion by tumor but lymph node metastasis can occur even in the 
absence of capsular or vascular invasion. The prognosis is excellent. 
DIFFUSE SCLEROSING VARIANT
The diffuse sclerosing variant  affects children and adults. It is more aggressive than 
conventional  papillary  carcinoma,  as  manifested  by  a  higher  incidence  of  lymph  node 
metastasis  and  frequent  distant  metastasis.  Thyroid  shows  diffuse  replacement  of  the 
parenchyma by white firm tissue which is gritty on cutting. The typical histological features 
include:  Diffuse  involvement  of  one  or  both  lobes,  sclerosis,  heavy  lymphoplasmacytic 
infiltrate,  abundant  psammoma bodies,  scattered  small  islands  of  papillary  carcinoma with 
prominent squamous or squamoid differentiation and extensive lymphatic permeation55,56.
DIFFUSE FOLLICULAR VARIANT 
This  rare,  aggressive  form of  papillary  carcinoma  occurs  in  young  patients,  and  is 
characterized by diffuse involvement of  the entire thyroid without formation of discernible 
nodules, an exclusive or predominant follicular pattern and absence of fibrosis. 
MACROFOLICULAR VARIANT
These are tumors with >50% area composed of large follicles57. 
TRABECULAR VARIANT
This variant shows trabecular growth pattern in over 50% of the tumor. Tumor cells are 
cuboidal or columnar with the cells oriented perpendicularly in the long straight trabeculae. It is 
associated with poor prognosis. 
CRIBRIFORM – MORULAR VARIANT
Shows a prominient cribriform pattern with interspersed squamous morules that harbour 
nuclei filled with lightly eosinophilic homogenous, biotin containing inclusions. 
Characteristically the luminal spaces are devoid of colloid. The tumor cells are cuboidal, 
columnar or attenuated but can be plump, spindle – shaped forming fascicles and whorls58. 
Nuclei are often chromatin rich, but nuclear features of typical papillary carcinoma can be seen 
focally. 
PAPILLARY CARCINOMA WITH LIPOMATOUS STROMA
In  rare  cases,  adipocytes  are  interspersed  within  the  papillary  
carcinoma59. 
VARIANT WITH EXUBERANT NODULAR FASCIITIS - LIKE STROMA
 Stroma is composed of spindle cells lying in a vascularised fibromyxoid matrix with 
extravasated red cells60. 
TALL CELL VARIANT 
Tumor composed predominantly of cells whose heights are at least three times their 
widths. More aggressive than conventional papillary carcinoma. 
COLUMNAR CELL VARIANT 
Characterised by mixed papillary, complex glandular, cribriform and solid pattern. The 
papillae are lined by tall columnar cells with  hyperchromatic oval or elongated nuclei. 
OXYPHILIC (ONCOCYTIC, HURTHLE CELL) VARIANT
Variant composed predominantly of cells with abundant eosinophilic granular cytoplasm 
due to accumulation of mitochondria. 
WARTHIN TUMOR LIKE VARIANT 
Papillary  pattern with rich  lymphoplasmacytic  infiltrate  in  the  cores  of  the  papillae. 
Cells that cover the papillae often have an oxyphilic appearance and can be tall61, 62. 
CLEAR CELL VARIANT
Exhibit extensive cytoplasmic clearing , usually due to accumulation of glycogen63.
VARIANT WITH SPINDLE CELL METAPLASIA 
Papillary carcinoma can exhibit a component of spindle shaped tumor cells, which can 
constitute a minor to major proportion of the entire tumor64. 
DEDIFFERENTIATED PAPILLARY CARCINOMA
Co-existence of papillary carcinoma with an undifferentiated or poorly differentiated 
thyroid carcinoma . Prognosis is bad. 
MICROCARCINOMA (PAPILLARY MICROTUMOR) 
Incidentally discovered papillary carcinoma with size <1cm, but not clinically evident 
small sized papillary carcinomas. 
IMMUNOHISTOCHEMISTRY 
Stain for pan – cytokeratin, thyroglobulin, and TTF-1.
Prognostic factors in papillary carcinoma
Age : Mortality very low in patients under the age of 40 years
Sex : Male sex is associated with worse prognosis
Size : 1-1.5cm excellent prognosis. >4cm poor prognosis
Stage : Extrathyroidal extension – poor prognosis. 
Tumor 
encapsulation :  Tumor encapsulation confers a favourable  prognosis.
Histological 
Variants : Tall cell, diffuse sclerosing diffuse follicular, solid, 
   trabecular, dedifferentiated variants – more aggressive. 
Completeness 
of tumor 
excision :  Incomplete tumor excision increases the risk of recurrence. 
Hashimoto’s thyroiditis or chronic lymphocytic thyroiditis is the most common cause of 
hypothyroidism in areas of the world where iodine levels are sufficient. It is characterized by 
gradual  thyroid  failure  because  of  autoimmune  destruction  of  thyroid  gland  .The  name 
Hashimoto’s thyroiditis is derived from the 1912 report by Hashimoto describing the patients 
with goiter and intense lymphocytic infiltration of the thyroid (struma lymphomatosa) . This 
disorder is most prevalent between 45 and 65 years of age and is more common in women than 
in men, with a female predominance of 10:1 to 20. Although it is primarily a disease of older 
women, it can occur in children and is a major cause of non endemic goiter.
Epidemiologic  studies  have  demonstrated  a  significant  genetic  component  to 
Hashimoto’s  thyroiditis,  although,  as  in  most  other  autoimmune  disorders  ,the  pattern  of 
inheritance is  Non- Mendelian  and  is likely to be influenced by subtle variations in the 
functions of multiple genes.  Several  chromosomal abnormalities  have been associated with 
thyroid auto immunity. 
Hashimoto’s thyroiditis is an auto immune disease in which the immune system reacts 
against  a  variety  of  thyroid antigens.  There  is  a  progressive depletion of thyroid follicular 
epithelial cells, which are gradually replaced by mononuclear cell infiltration and fibrosis. 
Multiple  immunologic  mechanisms  may  contribute  to  the  death  of  thyrocytes. 
Sensitization  of  autoreactive  CD4+T-helper,  cells  to  thyroid  antigens  appears  to  be  the 
initiating events. The effector mechanisms for thyrocyte death include the following.
1. CD8+ cytotoxic T cell-mediated cell death
2. Cytokine-Mediated cell Death 
Binding of antithyroid antibodies (anti-TSH receptor antibodies, antithyroglobulin, and 
antithyroid  peroxidase  antibodies)  is  followed  by  antibody  –dependent  cell-mediated 
cytotoxicity (ADCC).
The thyroid is often diffusely enlarged, although more localized enlargement may be 
seen in some cases.  The capsule is intact,  and the gland is well  demarcated from adjacent 
structures. The cut surface is pale, yellow-tan, firm and somewhat nodular. 
Microscopic  examination  reveals  extensive  infiltration  of  the  parenchyma  by  a 
mononuclear  inflammatory  infiltrate  containing small  lymphocytes,  plasma cells,  and well-
developed germinal centers. The thyroid follicles are atrophic and are lined in many areas by 
epithelial  cells  distinguished by the presence of  abundant  eosinophilic,  granular  cytoplasm, 
termed Hurthle cells. 
This  is  a  metaplastic  response of  the  normally  low cubodial  follicular  epithelium to 
ongoing injury. In fine-needle aspiration biopsies, the presence of Hurthle cells in conjunction 
with a heterogeneous population of lymphocytes is characteristic of Hashimoto thyroiditis. In 
“Classic”  Hashimoto’s  thyroiditis,  interstitial  connective  tissue  is  increased  and  may  be 
abundant. 
A  fibrous  variant  is  characterized  by  severe  thyroid  follicular  atrophy  and  dense 
“Keloid-like” fibrosis, with broad bands of acellular collagen encompassing residual thyroid 
tissue. Unlike Riedel’s thyroitidis, the fibrosis does not extend beyond the capsule of the gland. 
The remnant thyroid parenchyma demonstrates features of chronic lymphocytic thyroiditis.
Immunohistochemically,  the  follicular  cells  of  autoimmune  thyroiditis  show  great 
reactivity for keratin (particularly the high-molecular-weight for types), S-100 protein HLA-
DR,  and  N-acetyl-a-D-galactosamine  than  the  corresponding  normal  cells,  their 
immunohistochemical  profile  thus  resembling  that  of  the  cells  of  papillary  carcinoma. 
Biochemically,  the  oncocytic  cells  of  Hashimoto’s  thyroditis  have  defects  of  cytochrome 
oxidase and deletion of mitochondrial DNA.
Squamous nests, thought to arise from metaplasia of follicular cells, are common and 
can reach sizable proportions. Rarely, large cysts lined by squamous epithelium and bordered 
by row of lymphoid follicles are seen, their appearance being highly reminiscent of branchial 
cleft cysts. Parenthetically, similar cysts can be also be seen in the absence of thyroiditis.
In the typical case of Hashimoto’s thyroiditis, connective tissue is scanty, with slight or 
moderate  thickening of  the  interlobular  septa.  In  the  fibrous  variant  of  this  disease,  which 
comprises about 12% of all cases, fibrosis is more extensive.
The fibrous  variant  of  Hashimoto’s  thyroiditis  can also be confused with carcinoma 
when the fibrosis is associated with epithelial islands showing squamous metaplasia. Clinically, 
this variant characterized by a very firm goiter (often with sudden enlargement) severe pressure 
symptoms physical signs suggestive of cancer, and markedly elevated red cell antibody titer to 
thyroglobulin.
Although Hashimoto’s thyroiditis typically exhibits, a diffuse appearance both grossly 
and microscopically, cases do occur in which a distinct nodularity is evident, the eptithelial 
component  of  the  nodules  having  a  hyperplastic  quality.  This  could  be  interpreted  as  the 
combination of Hashimoto’s thyroiditis and nodular hyperplasia, but in all likelihood the two 
abnormalities  are  pathogenetically  related.  A term such as  nodular  Hashimoto’s  thyroiditis 
would therefore  seem more appropriate  to  designate  this  relatively  common occurrence.  A 
variation on the theme is represented by the Hashimoto’s thyroiditis in which one or more 
distinct hyperplastic  (“dominant”) nodules exclusively composed of Hurthle cells having either 
a follicular or a solid configuration are present.  
Complications of Hashimoto’s thyroiditis include malignant lymphoma and lukaemia , 
papillary carcinoma and Hurthle cell neoplasms. The occurrence of striking nuclear clearing 
and  overlapping  in  the  follicular  cells  of  Hashimoto’s  thyroiditis  is  of  interest.  There  is 
convincing evidence for an increase in the incidence of papillary carcinoma in Hashimoto’s 
thyroiditis but the wide variation in figures quoted suggests that the diagnostic criteria vary just 
as widely65.
Recently it has been shown that RET/PTC expression can also occur in benign thyroid 
lesion like Hashimoto’s thyroiditis66. Several authors have suggested an association between 
Hashimoto’s thyroiditis and papillary carcinoma67,68.
The RET/PTC rearrangement is highly specific for papillary thyroid carcinoma and is 
associated with characteristic nuclear features seen in papillary thyroid carcinoma. There is an 
overlap  in  the  morphological  features,  immunohistochemical  staining  pattern,  and  most 
importantly,  molecular  profile  between  papillary  thyroid  carcinoma  and  Hashimoto’s 
thyroiditis.  Hashimoto’s  thyroiditis  almost  always harbours  a  genetic  rearrangement  that  is 
strongly associated with and is highly specific for papillary thyroid carcinoma. Submicroscopic 
foci must be present in Hashimoto’s thyroiditis , although the clinical behavior is still benign69.
It has been established that papillary thyroid carcinoma is more frequent in Hashimoto’s 
thyroiditis  and  also  that  the  increased  incidence  of  occult  microscopic  papillary  thyroid 
papillary carcinoma is high70. 
PTC  associated  proteins  like  GAL3,  CITED,  CK19,  FN1  and  HBME1  are  focally 
expressed in Hashimoto’s thyroiditis in thyrocytes with PTC like nuclear changes suggesting 
shared molecular features between these thyrocytes and PTC. 
These  changes  are  quantitatively  different,  being  diffuse  in  PTC  and  focal  in 
Hashimoto’s thyroiditis, raising the possibility of activation of PTC associated genes in latter 
leading to premalignant transformation in cases of Hashimoto’s thyroiditis71,72.
It  is  hypothesized  that  papillary  thyroid  carcinomas,  which  may  be  associated  with 
squamous metaplastic changes, might express p63, whereas other thyroid neoplasms that lack 
the capacity for squamous differentiation might be p63 negative. A high percentage of p63 
positive foci has been described in most cases of papillary carcinoma thyroid and Hashimoto’s 
thyroiditis, in contrast with the uncommon to absent p63 expression in other primary thyroid 
neoplasms.  These  findings  raise  the  possibility  that  p63  expression  may  constitute  a 
mechanistic link between Hashimoto’s thyroiditis and papillary carcinoma.73
p63
p63 gene is structurally similar  to the p53 gene, consisting of 5’ region that codes for a 
protein moiety that activates transcription of same genes activated by p53, a central sequence 
coding for a DNA-binding region, and a3’ sequence coding for an oligomerization-promoting 
region. 
          The p63 gene codes for 6 protein isoforms based on alternate splicing and the existence 
of  2  promoters,  one  conventional,  the  other  a  biologically  active  internal  promoter  that 
generates truncated p63 proteins that fail to activate transcription and act as dominant negative 
blockers of p53 protein actions.74 
p63 has been  postulated to have a critical role in maintaining the integrity of squamous 
and other  epithelia  by  maintaining  the  balance between basaloid stem cell  commitment  to 
undergo  amitotic  differentiation  versus  retention  of  a  dividing  undifferentiated  stem  cell 
phenotype. 
To date p63 expression has been demonstrated in basal layers of squamous epithelia, 
urothelium, basal layers of prostate gland epithelia, myoepithelial cells of, submucosal gland 
epithelia and in the basal reserve cells of ciliated bronchial epithelia,75.
p63 is hypothesized to play an important role in maintaining the epidermal stem cell 
population. Immunohistochemical analyses show p63 protein localization and expression in 
basal /progenitor cells of several epithelial tissues such as epidermis mammary glands, prostate 
and urogenital tract. p63 expression is lost as these cells migrate from the basal layer  and 
become terminally differentiated cells.
In  thyroid,  it  is  hypothesized  that  papillary  thyroid  carcinomas  and  Hashimoto’s 
thyroiditis which may be associated with squamous metaplastic changes, might express p63 
whereas other thyroid neoplasms that lack the capacity for squamous differentiation might be 
p63 negative76.
IMMUNOHISTOCHMISTRY
Immunohistochemistry (IHC) involves two disciplines – immunology and histology.
Immunohistochemistry  is  used  to  determine  expression  of  particular  antigen  and  its 
micro  anatomic  location  in  the  tissue.  IHC  uses  antibodies  to  distinguish  the  antigenic 
differences  between  the  cells.  The  differences  can  specifically  identify  the  lineage  of  cell 
population and define biologically distinct populations of cells within the same lineage.
Immunohistochemistry started in 1940 when Coons developed all immunofluoresence 
technique to detect corresponding antigens in frozen sections.
Taylor and colleagues in 1947 showed that it was possible to demonstrate antigens in 
routinely processed tissue. Antigen retrieval technique was introduced by Shi and associates in 
1991.  It  is  a  simple  method  that  involves  heating  paraffin  processed  sections  at  high 
temperatures before IHC staining.
The use of antibody in IHC depends upon the sensitivity and specificity of the antigen – 
antibody reaction and the Hybridoma technique provides limitless source of highly specific 
antibodies.
BLOCKING NON-SPECIFIC BACKGROUND STAINING
Background staining is due to either non-specific binding or presence of endogenous 
enzymes.  Non  specific  binding  with  polyclonal  primary  antibody  is  minimized  by  pre-
incubating sections with serum from same species on optional working dilution.
Endogenous   enzymes  such  as  peroxidase  seen  in  normal  and  neoplastic  tissues  is 
abolished by peroxidase blocking or by using alternate systems such as immunogold technique.
Methods suggested to  overcome endogenous activity  include incubation in  methanol 
containing 0.5% hydrogen peroxide for 10 min at room temperature (almost complete abolition 
of endogenous peroxidase activity). Endogenous alkaline phosphatase is blocked by addition of 
0.1M concentration of levamisole to the enzyme substrate solution.
DETECTION SYSTEMS
Antibodies are labeled or flagged by some method to permit visualization these include 
fluorescent  substances,  enzymes  forming  coloured  reaction  with  suitable  substrate  (light 
microscopy) or heavy metals (Electron microscopy).
METHODS OF IHC
DIRECT LABELING METHOD
Antibody is  attached with  a  label  by  chemical  means  and directly  applied to  tissue 
sections. It is a rapid and easy procedure and caries the disadvantage of detection of multiple 
antigens which require separate incubation with respective antibodies.
INDIRECT LABELING METHOD
Enzymes are labeled with the secondary antibody, which is produced against primary 
antibody.  This  method  is  more  sensitive  and easy  to  handle.  The  advantages  also  include 
increased versatility, higher working dilution of primary antibody, secondary antibodies against 
primary antibodies of a different species easy to prepare.
AVIDIN – BIOTIN TECHNIQUES
High affinity  binding  between biotin  and avidin is  used in  this  procedure.  Biotin  is 
chemically linked to primary antibody and avidin is conjugated chemically to enzyme. The 
avidin  binds  to  biotinylated  antibody  thus  localizing  the  peroxidase  moiety  at  the  site  of 
antigen.
Disadvantage  of  this  technique  is  that  endogenous  biotin  produces  nonspecific 
background staining.
AVIDIN BIOTIN CONJUGATE PROCEDURE
In this technique primary antibody is added followed by biotinylated secondary antibody 
and next by preformed complexes of avidin and biotin horse radish peroxidase conjugate. This 
is a more sensitive method.
BIOTIN STREPTAVIDIN SYSTEM
Streptavidin is used in place of avidin. Streptavidin complexes are more stable.
IMMUNOGOLD SILVER STAINING TECHNIQUE
This is used in ultrastructural immunolocalisation. Gold particles are enhanced by the 
addition of several layers of metallic silver. The fine silver deposits in the background create 
confusion when small amounts of antigen are identified.
POLYMERIC METHOD 
This  technique  permits  binding  of  large  number  of  enzyme molecules  to  secondary 
antibody via the Dextran backbone. The advantages of this technique are increased sensitivity, 
minimized non specific background staining and a reduction in the total number of assay steps. 
FIXATION
This is a critical step as the preservation of morphology is essential for interpretation of 
IHC. 10% buffered neutral formalin is commonly used because of the following advantages:
1. Good morphological preservation.
2. Cheap.
3. Sterilizes tissues.
4. Carbohydrate antigens are better preserved.
The disadvantage of masking of antigens during fixation can be overcome by antigen 
retrieval technique.
ANTIGEN RETRIEVAL
This procedure involves unmasking of the antigens. The following techniques can be 
used.
1. Proteolytic enzyme digestion.
2. Microwave antigen retrieval
3. Microwave and trypsin antigen retrieval technique.
4. Pressure cooker antigen retrieval
MATERIAL AND METHODS
SOURCE OF DATA
Thyroidectomy  (Hemi,  Subtotal  and  total  thyroidectomy)  cases   received  in  the 
Department of Pathology, Stanley Medical College from the Department of Surgery during the 
study period from  May 2008 to September 2009
INCLUSION CRITERIA
 All cases of Hashimoto’s thyroiditis, papillary carcinoma and Hashimoto’s thyoiditis 
with papillary carcinoma irrespective of patient’s age and sex were included in the study.
EXCLUSION CRITERIA
All other thyroid lesions and cases with poor clinical data were excluded from the study.
METHOD OF DATA COLLECTION
A total of 195 cases received in the department during the study period were taken for 
study.  The  tissues  so  obtained  were  processed  and  sections  were  cut  at  5  microns  using 
Shandon semiautomatic microtome. Hematoxylin and eosin staining of the sections were done 
and  various  histomorphological  changes  were  studied.  Necessary  photomicrographs  were 
taken.
Histopathological diagnosis of the specimens studied included  adenoma, adenomatous 
goitre, nodular goitre, colloid goitre, toxic goitre, multinodular goitre, Hashimoto’s thyroiditis 
and papillary carcinoma. 
Out of 195 cases, 72 cases were taken for study out of which 38 cases were Hashimoto’s 
thyroiditis, 7 cases were Hashimoto’s thyroiditis with papillary carcinoma and 27 cases were 
papillary carcinoma . 21 cases were selected randomly, 7 cases from each of the above three 
category for immunohistochemical study of p63 immunoprotein status.  Section from cervix 
was taken as control to study p63 immunoprotein status(Fig.25,26). Only 21 cases were studied 
because of the cost effectiveness in doing immunohistochemical studies.
METHOD OF TISSUE PREPARION FOR IHC
10% neutral  buffered  formalin  was  used  for  fixing  the  specimens,  the  tissues  were 
processed in various grades of alcohol and xylene using automated histokinette. Paraffin blocks 
were prepared and sections of 5 microns thickness were cut using Shandon semi automatic 
microtome using disposable blades and stained with hematoxylin and eosin. Suitable blocks 
were chosen for IHC.
Sections for  immunohistochemistry were also cut  in semiautomatic microtome using 
disposable  blades.  Slides  coated  with  chrome alum were  used.  Sections  were  subjected  to 
antigen retrieval using the microwave technique using EDTA (PH 8) buffer solution and then 
treated by HPR (Horse radish peroxidase) polymer technique.
HRP POLYMER TECHNIQUE
The coated slides were taken through the following stages.
 Treatment with peroxidase block-for inhibiting endogenous peroxidases in the 
tissue for 20 minutes.
 Washed in TRIS buffer for 5 minutes.
 Application of power block- to block non specific antigen antibody reaction – 
20 minutes.
 Blot dried the excess power block.
 Application of primary antibody for 60 minutes.
 Washed in TRIS buffer for 5 minutes thrice.
 Application  of  super  enhancer  for  30  minutes  which  enhanced  the  final 
reaction product by increasing the sensitivity of antigen antibody reaction.
 Application of SS label – secondary antibody from goat with the tagged horse 
radish peroxidase enzyme for 30 minutes.
 Wash thrice in TRIS buffer.
 Application of DAB (Diamino benzidino) chromogen for 5 minutes – this was 
cleaved by the enzyme to give the coloured product at the antigen sites.
 Washed in distilled water for 5 min.
 The slides were counterstained with hematoxylin.
Air dried and mounted with DPX (Distrene dibutyl pthalide in xylol). 
p63 nuclear staining pattern and staining intensity ranged from strong to moderate to 
weak. Staining was focal rather than extensive or confluent.  Extent of staining varied from 
multiple positive foci to scattered or rare foci.
METHODS OF SCORING
Included measurements of the intensity of staining or percentage of positive cells or a 
combination of the two.
SCORE FOR INTENSITY OF STAINING OF p63
 0-no staining 
 1-weak staining 
 2-moderate staining 
 3-strong staining 
 Given a maximum score of 300 if 100 percent of tumor cells show strong positivity  
SCORE FOR PROPORTION OF POSITIVE CELLS 
 0- less than 5% positive nuclei 
 1- 5 to 25% positive nuclei 
 2- 26 to 75% positive nuclei
 3- over 75% positive nuclei
PERCENTAGE METHOD
Positivity  of  cells  was  defined  regardless  of  staining  intensity.  More  than  10%  of 
positive cells represented the cut off between negativity and positivity76.
OBSERVATION AND RESULTS
 A total of 195 biopsy samples were studied. The various thyroid lesions were classified 
based on the morphology
NON NEOPLASTIC LESIONS
 Adenomatous goiter : 33
 Multinodular goiter :  37
 Colloid goiter :  26
 Hashimoto’s thyroiditis (Fig.1-4) :  38
 Toxic goiter :    3
NEOPLASTIC LESIONS
 Follicular adenoma : 23
 Hashimoto’s thyroiditis 
with Papillary carcinoma (Fig.5-12) : 27
  Papillary carcinoma (Fig.13-24) :   7
 Medullary carcinoma :   1
CASE DISTRIBUTION IN DIFFERENT CATEGORIES
TABLE NO - 1
Category No of cases
Hashimoto’s thyroiditis 38
Papillary carcinoma 27
Hashimoto’s thyroiditis with Papillary 
carcinoma
7
Medullary carcinoma 1
Colloid goiter 26
Multinodular goiter 37
Adenomatous goiter 33
Toxic goiter 3
Follicular adenoma 23
TOTAL 195
CASE DISTRIBUTION IN DIFFERENT CATEGORIES
AGE DISTRIBUTION OF THYROID LESIONS
TABLE NO - 02
Age No of cases
10 to 19 7
20 to 29 44
30 to 39 69
40 to 49 46
50 to 59 20
60 to 69 6
70 to 79 3
TOTAL 195
AGE DISTRIBUTION OF THYROID LESIONS
Age range was from 16 to 75 years. Majority of cases belonged to 30 to 39 years age 
group followed by 40-49 years age group
AGE DISTRIBUTION OF THYROID LESIONS
SEX DISTRIBUTION 
Out of 195 cases, 178 were female patients and 17 were male patients.
IMMUNO HISTOCHEMISTRY RESULTS:
Immunohistochemical analysis of p63 was done in 21 cases which included 7 cases of 
Hashimoto’s thyroiditis, 7 cases of papillary carcinoma and 7 cases of Hashimoto’s thyroiditis 
with papillary carcinoma. Cases were selected randomly.
p63 immunostain staining intensity was observed and tabulated as follows:-
TABLE NO - 3
S.No Biopsy No. HPE Diagnosis p63 reactivity
1. 20/08 Hashimoto’s thyroiditis Weak
2. 69/08 papillary carcinoma Strong
3. 782/08 Hashimoto’s thyroiditis Negative
4. 816/08 Hashimoto’s thyroiditis Negative
5. 935/08 Hashimoto’s thyroiditis Negative
6. 2156/08 Hashimoto’s  thyroiditis  with 
papillary carcinoma 
Negative
7. 2273/08 Hashimoto’s  thyroiditis  with 
papillary carcinoma
Negative
8. 2702/08 Hashimoto’s thyroiditis Negative
9. 2729/08 Hashimoto’s  thyroiditis  with 
papillary carcinoma
Negative
10. 3197/08 Hashimoto’s  thyroiditis  with 
papillary carcinoma
Negative
11. 3340/08  papillary carcinoma Moderate
12. 3602/08 papillary carcinoma Weak
13. 3872/08 Hashimoto’s  thyroiditis  with 
papillary carcinoma
Negative
14. 153/09 Hashimoto’s thyroiditis  Negative
15. 797/09 Hashimoto’s thyroiditis Negative
S.No Biopsy No. HPE Diagnosis p63 reactivity
16. 831/09 papillary carcinoma Strong
17. 868/09 papillary carcinoma Moderate
18. 2494/09 papillary carcinoma Moderate
19. 2535/09 Hashimoto’s  thyroiditis  with 
papillary carcinoma
Negative
20. 2730/09 Hashimoto’s  thyroiditis  with 
papillary carcinoma
Negative
21. 2923/09 papillary carcinoma Weak
 
The above results show that all isolated cases of papillary carcinoma showed weak to 
strong reactivity of p63 (Fig.31-34). One case of Hashimoto’s thyroiditis showed occasional 
weak reactivity (Fig.27-30) and all cases of Hashimoto’s thyroiditis with concurrent papillary 
carcinoma and other cases of Hashimoto’s thyroiditis were negative.
The  theory  of  common  precursor  stem  cell  origin  of  Hashimoto’s  thyroiditis  and 
papillary  carcinoma    could  not  be  confirmed.  Similar  previous   studies  (73)  had  shown 
equivocal  results  and  stated  that  p63  positivity,  although  common  to  papillary  carcinoma, 
Hashimoto’s thyroiditis and thyroid cells with squamoid features, the possible mechanistic role 
in linking these various entities could not be proved.
DISCUSSION
Papillary carcinoma of the thyroid is the most common malignant tumor of the thyroid 
accounting for 80% of all thyroid cancers. Overall, it accounts for 1 % of all cancers.
These tumors may arise at any age but are most common between 3-5th decades16,17 and 
twice as common in women18.
The linkage of Hashimoto’s thyroiditis to papillary thyroid carcinoma is a matter of 
controversy. The increased risk of developing papillary carcinoma in patients with Hashimoto’s 
thyroiditis ranges from 0-30% 1
In  the  present  study,  a  total  of  195 samples  were  studied  and various  lesions  were 
classified based on histomorphology.
Based on histomorphology non neoplastic lesions outnumbered neoplastic lesions and 
all the thyroid lesions were found to be more common in females. 
Out of 195 cases 72 cases were taken for study. Of 72 cases, 27cases were papillary 
carcinoma and 45 cases were Hashimoto’s thyroiditis out of which 7 cases of Hashimoto’s 
thyroiditis were associated with papillary carcinoma.
Among the non neoplastic lesions Hashimoto’s thyroiditis was incidentally found to be 
more commonly associated with papillary carcinoma than others.
An attempt was made here to ascertain the possible association between Hashimoto’s 
thyroiditis and papillary carcinoma. 
The possible association between Hashimoto’s thyroiditis   and papillary carcinoma was 
studied in cases of Hashimoto’s thyroiditis, Hashimoto’s thyroiditis with papillary carcinoma 
and papillary carcinoma. 21 cases were selected randomly which included equal number of 
cases from each of the above three categories. p63 immunoprotein status was studied in these 
cases.
In  the  current  study,  p63 was detected in  all  cases  of  papillary carcinoma.  Staining 
intensity ranged from strong to moderate to weak to moderate but distinct. Staining was focal 
rather  than extensive or  confluent.  Extent  of  staining varied from multiple  positive  foci  to 
scattered to rare foci.
One case of Hashimoto’s thyroiditis showed occasional focal p63 staining in follicle like 
groupings.
All  cases  of  Hashimoto’s  thyroiditis  with  concurrent  papillary  carcinoma  were  p63 
negative.
 The results obtained from this study also co-rrelates with the previous literature results 
(Table - 4)
Name of the study
No of cases 
of 
hashimoto’s 
thyroiditis
No of cases 
of 
papillary 
carcinoma
No of cases of 
hashimoto’s
Thyroiditis 
with 
papillary 
carcinoma
Hashimoto’s 
thyroiditis
Papillary 
carcinoma
Hashimoto’s 
with
Papillary 
carcinoma
Pamela unger et. al . 
Human pathology 
2003
13 33 17
9/13
(69.2%)
27/33
(81.8%)
15/17
(88.2%)
Jorge S et.al . Modern 
pathology 2003
_ 6 _ _
6/6
(100)
_
Dina BL Demellawy 
et.al diagnostic 
pathology
_ 75 _ _
52/75
(70%)
_
Present study 
38 27 7
1/38
(0.026%)
27/27
(100%)
_
These  studies  have  also  shown  equivocal  results  regarding  the  p63  immunoprotein 
expression  in  cases  of  Hashimoto’s  thyroiditis  with  papillary  carcinoma.  Therefore  the 
association between Hashimoto’s thyroiditis and papillary carcinoma remains ambiguous.
Thus p63 positivity, although common to papillary carcinoma,   Hashimoto’s thyroiditis 
and thyroid cells with squamoid features, a mechanistic role in linking these various entities 
cannot be proved because of the following reasons.73
 Failure to explain the existence of p63 positive papillary carcinomas that occur in the 
absence of Hashimoto’s thyroiditis.
 Failure to account for p63 negative cases of Hashimoto’s thyroiditis.
 Failure of expression of p63 in all  cases of Hashimoto’s thyroiditis with concurrent 
papillary carcinoma. 
Therefore the theory of common precursor stem cell origin of Hashimoto’s thyroiditis 
and papillary carcinoma could not be confirmed in this study and molecular analysis are needed 
for definite confirmation.
SUMMARY AND CONCLUSION
A total of 195 thyroidectomy specimens were received during the period of study from 
May  2008  to  September  2009,  and  all  lesions  were  studied  histomorphologically. 
Immounhistochemical  analysis  of  p63  status  was  done  to  study  the  association  between 
Hashimoto’s thyroiditis and papillary carcinoma. 
The thyroid lesions were divided into to neoplastic and non neoplastic lesions and were 
further classified histologically.
Immonohistochemical analysis of p63 status was done in 21 cases selected randomly 
from cases of Hashimoto’s thyroiditis, Hashimoto’s thyroiditis with papillary carcinoma and 
papillary carcinoma. 
p63  positivity  was  found  in  all  cases  of  papillary  carcinoma,  occasionally  in 
Hashimoto’s  thyroiditis  and  absent  in  Hashimoto’s  thyroiditis  with  concurrent  papillary 
carcinoma.
The possible association between Hashimoto’s thyroiditis and papillary carcinoma could 
not be established because of occurrence of p63 negative cases of Hashimoto’s thyroiditis and 
lack of expression of p63 in all  cases of  Hashimoto’s thyroiditis  with concurrent papillary 
carcinoma.  Therefore  molecular  analysis  is  required  for  further  confirmation  of  their 
association.
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